Please login to the form below
acute coronary syndrome
This page shows the latest acute coronary syndrome news and features for those working in and with pharma, biotech and healthcare.
Novartis and Bayer among backers for European big data project
Its overarching aim is to improve patient outcomes and reduce the burden on society of atrial fibrillation (AF), heart failure (HF) and acute coronary syndrome (ACS).
Latest news
-
Another failed trial knocks back AZ's plan to grow Brilinta
Putting a brave face on the verdict, AZ's chief medical officer Sean Bohen said that the "proven benefits of Brilinta in acute coronary syndrome and post-myocardial infarction patients are
-
AZ's Brilinta disappoints in stroke trial
its approval in its current indication in acute coronary syndrome (ACS).
-
AstraZeneca wins EU approvals for Zurampic and Brilique
A 90mg dose of Brilique is already available in the EU for adults with acute coronary syndrome (ACS), but the approval of a 60mg dose means that patients with a history
-
Sanofi will resubmit Lyxumia for FDA approval in Q3
Although the 'Evaluation of Lixisenatide in Acute Coronary Syndrome' (ELIXA) trial failed to meet its original primary objective of demonstrating a reduction in cardiovascular morbidity and mortality, the results are still ... The type 2 diabetes study
-
Sanofi and Amgen poised for cholesterol drug sales
Data are due in 2017, according to Amgen. Meanwhile, Sanofi and Regeneron are carrying out the ODYSSEY OUTCOMES trial in patients with acute coronary syndrome (ACS) receiving "evidence-based medical therapy ... The primary outcome measure is a composite
More from news
Approximately 7 fully matching, plus 64 partially matching documents found.
Latest Intelligence
-
Why health psychology is the answer to tackling adherence
In one recent programme that we developed on behalf of AstraZeneca, we assessed the reasons for low adherence in patients with acute coronary syndrome (ACS) who had been prescribed Oral Antiplatelet
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
AZ names Brilique lead in Spain
In this role Gribble will be responsible for the company's marketing of Brilique (ticagrelor) for acute coronary syndrome, including management, development and market access activities, and he will also be ... to save the lives of thousands of people
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Dissecting adherence to personalise patient support
Molloy, G, et al. (2014). Intentional and unintentional non-adherence to medications following an acute coronary syndrome: a longitudinal study.
-
Understanding the "Big Picture"
A good example would be in acute coronary syndrome (ACS) where there is data to suggest that approximately 350, 000 males in the USA currently suffer from this syndrome.
More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.
Featured jobs
- Account Director – Global Healthcare PR
-
Salary TBC
-
Associate Medical Director
-
Highly Competitive
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 benefits
- Experienced Editor, London, Medical Communications
-
Competitive package
-
Scientific Team Lead
-
Competitive Salary
-
Scientific Director
-
Highly Competitive Salary &Benefits
-
Senior Account Manager - Med Comms
-
Highly Competitive Salary &Benefits
- Lead Medical Copywriter, Healthcare Brand Communications, London
-
Excellent package
- Account Manager, Healthcare Advertising
-
Salary TBC
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Director Healthcare PR Communications
-
Salary TBC
-
Associate Medical Director
-
Salary TBC
- Senior Account Manager / Account Director - Med Comms
-
Great salary and benefits
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
-
Account Director - Digital
-
Great salary and benefits
Subscribe to our email news alerts
- Retaining reader value in plain language summaries of clinical studies
- Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
- 90TEN wins big at PRWeek Awards taking home six accolades including Mid-Sized and Specialist Consultancy of the Year
- The NHS in 2022: how pharma can contribute to new models of care
- Genomics England chooses Congenica for diagnostic decision support
- Ocrevus surge keeps Roche smiling in Q3
PMHub
SpotMe
SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...
Latest intelligence
- Retaining reader value in plain language summaries of clinical studies
- Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
- Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
- Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
- Making Europe a leader in bioscience: boosting trust and opening minds
- A vision of Paris as Europe’s leading hub for life sciences innovation...
Quick links
Infographics
